State of the Art Course in Addiction Medicine 2022

4.85 (13 votes)

  • Register
    • Non-Member - $399
    • Regular Member - $299
    • Retired - $299
    • Early Career Physician - $299
    • Resident - $199
    • Student - $199
    • Associate - $199
    • ASAM Staff - Free!
    • International Member - $299
    • Emeritus Member - $299
    • Provisional Member - $299
    • Fellow Member - $299
    • Honorary Member - $299
    • CRT Member - $299
image

ASAM State of the Art Course Addiction Medicine 2022

Recorded on Thursday, September 29 - Saturday, October 1, 2022

Live In-Person & On-Demand Course

Overview

This 18 hour live course includes over 11 sessions highlighting best practices and the latest science, research, and innovations in addiction medicine from leading experts in the field.

These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:

  • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
  • Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
  • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine

This conference addresses all 6 ACGME Competencies.

Learning Objectives

At the end of the course, learners should be able to:

  1. Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
  2. Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
  3. Develop practical applications for integrating new and emerging science into practice.
  4. Identify gaps in the field of addiction medicine that future research can address.
  5. Create a network of colleagues and resources to support the learner’s practice or form future research collaborations.

Registration Rates

ASAM Learner TypeRate
ASAM Member$299
Non-Member$399
Associate Member$199
Resident Member*$199
Student Member*$199

*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

Refunds & Cancellations

All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

Registration Deadline: 10/1/2025

Instructions - Live

  1. Click on the Content tab to access the Evaluation.
  2. Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
  3. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.

Instructions - On-Demand

  1. Click on the Content tab to view all sessions within the course. Click the View button to access a specific session.
  2. Within each session, select the Content tab to begin the activity.
  3. Participants will need to complete post tests and evaluations after each session. Participants will have 10 attempts to pass and must answer 2 out of 3 questions correctly. Medical Credits are claimed within each session and are not available for the entire package.

Need Assistance?

For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

ACCME Accredited with Commendation

CME, CE, CEU and Other Credit Types


ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement 
The American Society of Addiction Medicine designates this enduring material for a maximum of 18 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NAADAC, the Association for Addiction Professionals
This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1222

California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205

California Consortium of Addiction Programs and Professionals (CCAPP)
This educational program is approved by CCAPP: #OS-20-330-1222

Continuing Education Credits (CEUs)
Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

Maintenance of Certification (MOC)


American Board of Medical Specialties (ABMS)

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, ASAM 53rd Annual Conference 2022 has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards: Allergy and Immunology, Anesthesiology, Colon and Rectal Surgery, Family Medicine, Medical Genetics and Genomics, Nuclear Medicine, Physical Medicine and Rehabilitation, Plastic Surgery, Preventive Medicine, Psychiatry and Neurology, Radiology, Thoracic Surgery, Urology

American Board of Preventive Medicine (ABPM)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 18 LLSA credits towards ABPM MOC Part II requirements.

American Board of Anesthesiology (ABA)
This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

American Board of Pediatrics (ABP)
Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 18 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 18 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credits.

American Board of Surgery (ABS)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and/or Self-Assessment requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

American Board of Psychiatry and Neurology (ABPN)
Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

American Board of Addiction Medicine (ABAM)
Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

Royal College of Physicians and Surgeons of Canada (RCPSC)
Royal College Fellows can use participation in Accredited Continuing Medical Education to earn Section 3 Credits.

Disclosure Information


In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include mitigating all possible relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity. 

  • Contains 2 Component(s), Includes Credits

    Complete the course evaluation and claim credit for sessions attended between September 29, 2022 and October 1, 2022. Attendees should claim only the credit commensurate with the extent of their participation in the activity.

    image

    ASAM State of the Art Course Addiction Medicine 2022

    Live In-Person Evaluation & Certificate

    Overview

    Complete the course evaluation and claim credit for sessions attended between September 29, 2022 and October 1, 2022. Attendees should claim only the credit commensurate with the extent of their participation in the activity.

    CME, CE, CEU and Other Credit Types

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this live activity for a maximum of 18 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals
    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)
    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)
    This educational program is approved by CADTP: #205

    California Consortium of Addiction Programs and Professionals (CCAPP)
    This educational program is approved by CCAPP: #OS-20-330-1222

    Continuing Education Credits (CEUs)
    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC) / Continuing Certification Program (CCP)
    The ASAM State of the Art Course and 2 pre-courses meets the CME requirements for the following primary boards:
    • American Board of Medical Specialties (ABMS)
    • American Board of Preventive Medicine (ABPM)
    • American Board of Anesthesiology (ABA)
    • American Board of Pediatrics (ABP)
    • American Board of Internal Medicine (ABIM)
    • American Board of Surgery (ABS)
    • American Board of Psychiatry and Neurology (ABPN)
    • American Board of Addiction Medicine (ABAM)
    • Royal College of Physicians and Surgeons of Canada (RCPSC)

    Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include mitigating all possible relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee member and Presenters have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    Instructions

    1. Click on the Content tab to access the Evaluation.
    2. Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
    3. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.

    Need Assistance?

    For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

    ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

  • Contains 8 Component(s), Includes Credits

    This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course reviews the latest research developments on the current an future impacts of COVID-19 and potential solutions.

    image

    COVID-19: Current and Future Impacts

    Recorded: Thursday, September 29, 2022 - Saturday, October 1, 2022
    On-Demand Session

    Overview

    This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course reviews the latest research developments on the current an future impacts of COVID-19 and potential solutions.
    The COVID-19 era has given rise to a series of major life stressors, including illness and death caused by a global pandemic, stay-at-home orders, disruptions in employment and income, food and supply shortages, as well as housing instability. As a result of these factors, epidemiological evidence suggests that the pandemic has increased alcohol use, opioid use, and the prevalence of certain psychological disorders. Furthermore, minoritized persons with substance use disorders are a particularly vulnerable population because of their unique social and health care needs, which place them at risk for significant harm from both the pandemic itself and its social and economic consequences. This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course explores the impacts of the COVID-19 pandemic as well as potential solutions. Following each presentation, presenters answer audience questions.

    This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.

    • Emerging Trends in Alcohol Misuse and Related Harms During and After the Pandemic
      Epidemiological evidence suggests a mixed picture for alcohol use during the COVID-19 pandemic.  Overall, there was a trend towards increased alcohol consumption, with some groups, including women, showing greater increases than others.  After increasing around 2.2% per year over the previous two decades, deaths involving alcohol jumped 25.5% between 2019 to 2020.  Mental health factors were the most common correlates or triggers for increased use of alcohol.  There is a need for increased vigilance for alcohol-related problems and there is likely to be an increase in the need for alcohol treatment.  Problematic alcohol use which is not addressed can lead to adverse consequences for individuals and families, and has significant costs for health systems.
    • Opioid Use Disorder Treatment without Red Tape? What We Learned During COVID-19
      Access to medications for opioid use disorder (MOUD), including methadone and buprenorphine, are substantially restricted by controlled substance regulations that present a burden to many patients. For example, methadone patients are typically required to travel to opioid treatment programs daily to receive observed doses of medication and buprenorphine patients have not historically been allowed to start medication based on a telephone or video consult. However, many regulations were suspended or modified after the COVID-19 public health emergency. This "natural experiment" has taught the field important lessons about possible new directions for increasing access, such as take home methadone and telehealth for buprenorphine, in a less burdensome manner. This talk will review the evidence in support of the argument for making the COVID-19 regulations permanent.
    • Racism, COVID-19, and Racial/Ethnic Behavioral Health Inequities
      Racial and ethnic minorities have shouldered a disproportionate medical, emotional and social burden of the COVID-19 pandemic. This presentation will discuss racial and ethnic disparities in COVID-19 infection and associated consequences. The presentation will highlight the contribution of structural racism on disparities in social determinants of health that place Black, Latinx and Other People of Color at increased risk for Covid-19 infection, morbidity and mortality. It will also explore the intersectionality of race and substance use disorder on COVID-related outcomes for minoritized populations, especially Black persons in the United States.
    • Symptoms of Psychological Distress Among U.S. Adults over the Course of the COVID-19 Pandemic
      This presentation will describe a longitudinal survey of a nationally representative cohort of U.S. adults measuring psychological distress in April 2020, July 2020, November 2020, and July 2021. Study results include measures of psychological distress, using the validated Kessler-6 measure, at each time point, as well as measures of treatment seeking and receipt. Discussion will focus on the trajectory of psychological distress over the course of the COVID-19 pandemic among U.S. adults overall and among specific demographic sub-groups. The presentation will conclude with consideration of the implications of study results for public mental health moving forward.

    These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:

    • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
    • Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
    • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine

    This conference addresses all 6 ACGME Competencies.

    Learning Objectives

    At the end of the course, learners should be able to:

    1. Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
    2. Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
    3. Develop practical applications for integrating new and emerging science into practice.
    4. Identify gaps in the field of addiction medicine that future research can address.
    5. Create a network of colleagues and resources to support the learner's practice or form future research collaborations.

    Registration Rates

    ASAM Learner TypeRate
    ASAM Member$29
    Non-Member$39
    Associate Member$19
    Resident Member*$19
    Student Member*$19

    *Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

    Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

    Refunds & Cancellations

    All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

    Registration Deadline: 10/1/2025

    Instructions

    1. Click on the Contents tab to begin this activity.
    2. Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
    3. Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
    4. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.

    Need Assistance?

    For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

    ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

    Michael Fingerhood, MD FACP DFASAM (Moderator)

    Associate Professor of Medicine and Public Health

    Johns Hopkins University

    Dr. Michael Fingerhood is an Associate Professor of Medicine and Public Health at the Johns Hopkins University. He is the Chief of the Division of Chemical Dependence and medical director of the Comprehensive Care Practice (CCP) at Johns Hopkins Bayview Medical Center. The CCP integrates substance use disorder treatment with primary medical care, including care for HIV and hepatitis C.

    No Relevant Financial Disclosures

    Aaron White, PhD

    Leader, Epidemiology and Biometry Branch and Senior Scientific Advisor to the Director

    National Institute on Alcohol Abuse and Alcoholism

    Aaron White is the Senior Scientific Advisor to the Director at the National Institute on Alcohol Abuse and Alcoholism (NIAAA). His areas of scientific expertise include the brain mechanisms and epidemiology of alcohol-induced memory blackouts, and the impact of alcohol and other drugs on brain function and behavior, particularly during the adolescent years.

    Dr. White co-wrote the online alcohol prevention course, AlcoholEdu, which has been completed by more than 3 million high school and college students to date. He joined NIAAA in 2008 and, until recently, was a Program Officer in the Division of Epidemiology and Prevention Research. As a Program Officer, Dr. White oversaw a large portfolio of grants covering epidemiology and prevention research related to underage and college drinking. In 2015, he was promoted to Senior Scientific Advisor to the Director, Dr. George Koob. In this position, Dr. White advises the Director regarding a wide variety of scientific topic areas in alcohol and other drug research.

    He also frequently takes part in media interviews and delivers presentations on behalf of the Institute, including presentations on addiction and overdoses at a meeting of the United Nations Office of Drugs and Crime in Austria last fall. He is an author on 37 peer-reviewed manuscripts, 22 review papers and book chapters, 3 books and has delivered several hundred presentations about alcohol and the brain.

    No Relevant Financial Disclosures

    Brendan Saloner, PhD

    Associate Professor

    Johns Hopkins Bloomberg School of Public Health

    Brendan Saloner, PhD, is a Bloomberg Associate Professor of Addiction and Overdose in the Department of Health Policy and Management. One strand of his research focuses on access and quality of care for people with mental health and substance use disorders. Professor Saloner has investigated the impact of federal and state policies regarding insurance coverage and benefit design related to substance use disorders on access to care and outcomes related to treatment. Dr. Saloner has examined the ability of people in the criminal legal system to access evidence-based substance use disorder treatment. He received an early career award from the National Institute on Drug Abuse to study the effects of Medicaid program design on treatment for opioid use disorder. Another strand of his research focuses broadly on insurance expansions and safety net programs for low-income populations. He has published widely on access to primary care services in relation to the Affordable Care Act Medicaid expansion. He has also published on Medicaid redesign related to premiums and cost-sharing and on public insurance programs for children and adolescents. Finally, Professor Saloner has studied the ethics of resource allocation and normative issues related to health insurance policy.

    No Relevant Financial Disclosures

    Anika Alvanzo

    MD, MS, DFASAM, FACP

    Anika Alvanzo, MD, MS, DFASAM, FACP is the Eastern Region Medical Director for Pyramid Healthcare, Inc. She also serves as a physician consultant on substance use disorders to the Behavioral Health Administration in the Maryland Department of Health and is the Managing Partner of Uzima Consulting Group, LLC, which provides addiction medicine-related consultation, education and training, and expert witness testimony. Dr. Alvanzo is a graduate of the George Washington University School of Medicine and Health Sciences and holds a master’s degree in biostatistics from Virginia Commonwealth University. She is board certified in Internal Medicine and Addiction Medicine. Dr. Alvanzo is a Distinguished Fellow of ASAM, a Past President of the Maryland-DC Society of Addiction Medicine (MDDCSAM), and currently serves as Chair of the ASAM Annual Conference Program Planning Committee and Region V Director for the ASAM Board of Directors.

    At Pyramid Healthcare, Inc., Dr. Alvanzo’s role is to optimize and standardize the medical care, with emphasis on substance withdrawal management and pharmacotherapy, in the residential and outpatient addiction treatment programs in Eastern Pennsylvania and Maryland. Prior to this, Dr. Alvanzo spent twelve years as faculty in the Divisions of General Internal Medicine and Addiction Medicine at Johns Hopkins University School of Medicine where she held a variety of clinical leadership roles, including Associate Medical Director of Addiction Treatment Services and the Center for Addiction and Pregnancy and Medical Director of the Broadway Center for Addiction, comprehensive, outpatient substance use disorder treatment (SUD) programs on the Johns Hopkin Bayview and Johns Hopkins Hospital campuses, respectively. From 2011 – 2018, Dr. Alvanzo directed the Substance Use Disorders Consultation Service, a multidisciplinary addiction consultation service serving the Johns Hopkins Hospital Department of Medicine general and subspecialty services.

    Dr. Alvanzo has served as an expert on National Institutes of Health (NIH), Substance Abuse and Mental Health Services Administration (SAMHSA), National Academies of Sciences, Engineering and Medicine (NASEM), National Quality Forum (NQF) and PEW Research Center panels regarding opioids and integration of recovery-oriented care in various medical settings. 

    No Relevant Financial Disclosures

    Beth McGinty, PhD, MS

    Professor

    Johns Hopkins Bloomberg School of Public Health

    Dr. Beth McGinty is a Professor of Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health. At Johns Hopkins, Dr. McGinty serves as Co-Director of the Center for Mental Health and Addiction Policy Research and Co-Director of the ALACRITY Center for Health and Longevity in Mental Illness. Dr. McGinty is a mixed-methods researcher who studies the implementation and outcomes of mental health and substance use policies. She received her MS from Columbia University in 2006 and her PhD from the Johns Hopkins Bloomberg School of Public Health in 2013.

    No Relevant Financial Disclosures

    ACCME Accredited with Commendation

    CME, CE, CEU and Other Credit Types

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals
    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)
    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)
    This educational program is approved by CADTP: #205

    California Consortium of Addiction Programs and Professionals (CCAPP)
    This educational program is approved by CCAPP: #OS-20-330-1222

    Continuing Education Credits (CEUs)
    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC) / Continuing Certification Program (CCP)

    The ASAM State of the Art Course  meets the CME requirements for the following primary boards:
    • American Board of Medical Specialties (ABMS)
    • American Board of Preventive Medicine (ABPM)
    • American Board of Anesthesiology (ABA)
    • American Board of Pediatrics (ABP)
    • American Board of Internal Medicine (ABIM)
    • American Board of Surgery (ABS)
    • American Board of Psychiatry and Neurology (ABPN)
    • American Board of Addiction Medicine (ABAM)
    • Royal College of Physicians and Surgeons of Canada (RCPSC

    Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include mitigating all possible relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee member and Presenters have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

  • Product not yet rated Contains 9 Component(s), Includes Credits

    This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course explores new research in preventing, screening, and treating psychiatric disorders among people with substance use disorders. Topics include suicide, methamphetamine psychosis, ADHD, depression, and anxiety.

    image

    Co-Occurring Psychiatric Disorders

    Recorded: Thursday, September 29, 2022 - Saturday, October 1, 2022
    On-Demand Session

    Overview

    This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course explores new research in preventing, screening, and treating psychiatric disorders among people with substance use disorders. Topics include suicide, methamphetamine psychosis, ADHD, depression, and anxiety.
    There is a high prevalence of psychiatric comorbidity among people with substance use disorders, with some studies showing as high as 80% having another mental health condition. This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course explores new research in preventing, screening, and treating psychiatric disorders among people with substance use disorders. Topics include suicide, methamphetamine psychosis, ADHD, depression, and anxiety. Following the session, a moderated panel discussion among the presenters answers audience questions.

    This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.

    • Addiction, Overdose, Suicide & the Gray Areas in Between
      About 50,000 people die each year in the USA from Suicide and another 70,000 die from Overdoses, ( 50,000 from opioids). This presentation with review data and interactions about Suicide and Overdose, including clinical presentations and possible interventions which may affect either or both problems. Clinical screening methods for suicide have been developed and tested over many years and include both clinical and demographic issues. The role of substance use disorders has not previously been fully appreciated as a major risk factor, nor intervention in substance use disorders fully appreciated as a possible suicide intervention.
    • Over-amped: Managing Methamphetamine Use Disorder and Methamphetamine Psychosis
      Methamphetamine is among the common substances of abuse related to emergency service utilization; psychosis due to methamphetamine use may be mistaken for primary psychiatric illness but in fact requires quite different treatment. Early recognition and appropriate intervention is critical. This talk reviews the epidemiology of methamphetamine use in emergency settings and describes original data of a novel intervention for treating methamphetamine-induced psychosis. A structured, emergency department-initiated intervention illustrates core elements of engaging patients presenting with methamphetamine psychosis.
    • Treatment of ADHD and Substance Use Disorders
      Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders (SUD) are highly comorbid, with 15-20% of treatment-seekers for SUD having current ADHD. Individuals with SUD and ADHD are more likely to relapse and less likely to be retained in treatment than those without ADHD. To date, treatment trials targeting individuals with ADHD and SUD have produced mixed results. Data from 2 studies found that among adults with ADHD and stimulant use disorder, robust dosing produced clinically meaningful therapeutic effects on the ADHD symptoms and illicit stimulant use. However, prescribing prescription stimulants needs to be done carefully to mitigate the risks of nonmedical use and diversion. Pillars of safe prescribing include accurate diagnosis, clear and defined target outcomes and careful monitoring for misuse.
    • Depression and Anxiety in Patients with Addiction
      Co-occurring mood and anxiety disorders are highly prevalent among patients with substance use disorders, and if left untreated, they usually have a negative impact on addiction recovery. This session will review pharmacologic treatments for mood and anxiety disorders in the context of different substance use disorders (SUD). Principles of assessment and diagnosis will be presented since it is frequently unclear as to the source of mood and anxiety symptoms in the context of SUD that may be substance-induced and may or may not reach disorder-level severity or threshold. Then, when appropriate, stepped treatment strategies will be discussed.

    These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:

    • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
    • Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
    • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine

    This conference addresses all 6 ACGME Competencies.

    Learning Objectives

    At the end of the course, learners should be able to:

    1. Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
    2. Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
    3. Develop practical applications for integrating new and emerging science into practice.
    4. Identify gaps in the field of addiction medicine that future research can address.
    5. Create a network of colleagues and resources to support the learner's practice or form future research collaborations.

    Registration Rates

    ASAM Learner TypeRate
    ASAM Member$29
    Non-Member$39
    Associate Member$19
    Resident Member*$19
    Student Member*$19

    *Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

    Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

    Refunds & Cancellations

    All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

    Registration Deadline: 10/1/2025

    Instructions

    1. Click on the Contents tab to begin this activity.
    2. Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
    3. Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
    4. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.

    Need Assistance?

    For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

    ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

    Michael Fingerhood, MD FACP DFASAM (Moderator)

    Associate Professor of Medicine and Public Health

    Johns Hopkins University

    Dr. Michael Fingerhood is an Associate Professor of Medicine and Public Health at the Johns Hopkins University. He is the Chief of the Division of Chemical Dependence and medical director of the Comprehensive Care Practice (CCP) at Johns Hopkins Bayview Medical Center. The CCP integrates substance use disorder treatment with primary medical care, including care for HIV and hepatitis C.

    No Relevant Financial Disclosures

    Richard K. Ries

    MD, DFASAM

    Richard K. Ries, MD, is Professor of Psychiatry, and Director of the Addictions Division in the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine in Seattle, Washington and Director of the Addiction Treatment services at Harborview Medical Center in downtown Seattle. Dr. Ries received his undergraduate degree from Stanford, medical degree from Northwestern Medical School and completed his psychiatric residency at the University of Washington, Seattle, where he was Chief Resident. 

    Dr. Ries is board-certified in Psychiatry by the American Board of Psychiatry and Neurology with Added Qualifications in Addiction Psychiatry, and the American Board of Addiction Medicine.  A Distinguished Fellow of the American Psychiatric Association and a Fellow of the American Society of Addiction Medicine, he is on the editorial board and a reviewer for several scientific journals and holds a number of research grants from the National Institute of Health. 

    He has published numerous articles and abstracts on topics related to treatment of persons with severe mental illness, with special emphasis on those with co-existing problems with alcohol or drugs, and was the chair and co-chair of TIPS 9 and 42 on Treatment of Persons with Co-occurring  Addiction and Mental Disorders published by the national Center of Substance Abuse Treatment (CSAT).  He is senior editor of  the key reference text:  Principles of Addiction Medicine (edition V, 2014), published by the American Society of Addiction Medicine, and a noted expert in the  field of Addictions.

    No Relevant Financial Disclosures

    Scott Simpson

    MD, MPH

    Scott Simpson MD MPH is Medical Director of Psychiatric Emergency Services at Denver Health Medical Center and Assistant Professor of Psychiatry at the University of Colorado School of Medicine. Dr. Simpson has published on the management of substance use disorders in the emergency setting and part of the Denver Health team that launched Colorado's first 24/7 buprenorphine induction program. Dr. Simpson is board certified in general psychiatry, addiction medicine, and consultation-liaison psychiatry.

    Does Disclose: Royalties from Taylor & Francis for a clinical textbook unrelated to presentation content

    Margaret Chaplin, MD

    Psychiatrist

    Farrell Treatment Center, New Britain, CT Community Faculty, Department of Psychiatry, University of Connecticut Medical School, Farmington CT

    Dr. Margaret Chaplin, MD currently serves as Psychiatric Consultant to the Farrell Treatment Center in New Britain, CT. She is also on the Community Faculty of the Department of Psychiatry at UConn Health and a Principal Psychiatrist for the Capital Region Mental Health Center a
    Connecticut Department of Mental Health and Addiction Serivces Community Mental Health Center. She recieved her undergraduate education at Swarthmore College, her medical degree at Harvard Medical School and completed residency in psychiatry at University of Massachusetts Medical School. She is board certified in Psychiatry and Addiction Medicine and is a Mentor for the SAMSHA Provider Clinical Support System for the treatment of Opioid Use Disorder. Her area of interest is Comorbidity of SUD and Mental Health particularily with respect to Anxiety, ADHD and Insomnia.

    No Relevant Financial Disclosures

    Richard Rosenthal, MA, MD

    Professor of Psychiatry

    Renaissance School of Medicine at Stony Brook

    Richard Rosenthal, MA, MD is Professor of Psychiatry and was the Inaugural Director of Addiction Psychiatry at Stony Brook School of Medicine. His research has focused on evaluating and treating mentally ill patients with co-occurring addictive disorders and novel treatments for SUD. More recently he has developed his interest in medical informatics and machine learning strategies regarding identification and impact of non-medical opioid use. He has been active in research, education, program development, treatment and public policy related to addiction. Since 2003, he has held the chair of Public Policy at the American Academy of Addiction Psychiatry.

    Dr. Rosenthal received his MD at SUNY Downstate Medical Center and completed his psychiatry residency as Chief Resident at Mount Sinai Hospital. He later founded the Addiction Psychiatry program at Beth Israel Medical Center, NY, and directed one of the first ACGME-approved Addiction Psychiatry Fellowships in the US. As Chairman of Psychiatry at St. Luke’s Roosevelt Hospital Center (2001- 2014), he was Arthur J. Antenucci Professor of Psychiatry and Senior Associate Dean at Columbia University College of Physicians & Surgeons. He also served as Physician-in-Chief of the Behavioral Health Service Line of Continuum Health Partners until its 2013 merger with the Mount Sinai Health System.

    Dr. Rosenthal has served as president of the American Academy of Addiction Psychiatry and the American Association for Technology in Psychiatry. He is a Distinguished Life Fellow of the American Psychiatric Association, and a Distinguished Fellow of the American Academy of Addiction Psychiatry. Author of numerous articles, book chapters and books, he is also an Editor of the American Society of Addiction Medicine Principles of Addiction Medicine. In 2008, Dr. Rosenthal was the recipient of the Founders’ Award from the American Academy of Addiction Psychiatry. He has been selected for Castle Connolly America’s Top Doctors™ since 2008.

    Does Disclose: SOLVD Health, consulting payments, medical advisory panel, genetic testing for risk of developing opioid use disorder.

    ACCME Accredited with Commendation

    CME, CE, CEU and Other Credit Types

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals
    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)
    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)
    This educational program is approved by CADTP: #205

    California Consortium of Addiction Programs and Professionals (CCAPP)
    This educational program is approved by CCAPP: #OS-20-330-1222

    Continuing Education Credits (CEUs)
    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC) / Continuing Certification Program (CCP)

    The ASAM State of the Art Course  meets the CME requirements for the following primary boards:
    • American Board of Medical Specialties (ABMS)
    • American Board of Preventive Medicine (ABPM)
    • American Board of Anesthesiology (ABA)
    • American Board of Pediatrics (ABP)
    • American Board of Internal Medicine (ABIM)
    • American Board of Surgery (ABS)
    • American Board of Psychiatry and Neurology (ABPN)
    • American Board of Addiction Medicine (ABAM)
    • Royal College of Physicians and Surgeons of Canada (RCPSC

    Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include mitigating all possible relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee member and Presenters have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

  • Product not yet rated Contains 8 Component(s), Includes Credits

    This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course discusses research and treatment approaches for common co-occurring medical disorders, such as HCV, Drug Use-Associated Infective Endocarditis (DUA-IE), liver disease, and Skin and Soft Tissue Infections (SSTIs).

    image

    Co-Occurring Medical Disorders

    Recorded: Thursday, September 29, 2022 - Saturday, October 1, 2022
    On-Demand Session

    Overview

    This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course discusses research and treatment approaches for common co-occurring medical disorders, such as HCV, Drug Use-Associated Infective Endocarditis (DUA-IE), liver disease, and Skin and Soft Tissue Infections (SSTIs).
    Patients receiving addiction treatment frequently present with medical and psychological conditions that can greatly affect their overall well-being. This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course discusses research and treatment approaches for common co-occurring medical disorders, such as HCV, Drug Use-Associated Infective Endocarditis (DUA-IE), liver disease, and Skin and Soft Tissue Infections (SSTIs). Following each presentation, presenters answer audience questions.

    This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.

    • Removing "Alcoholic" from Alcohol Related Liver Disease
      Alcohol related liver disease and its consequences are on the rise. Identification of unhealthy alcohol use along with the provision of evidenced-based treatment can improve overall liver health. In this session, we will discuss alcohol related liver disease, its management, including the use of early liver transplant, and the importance of integrating care for alcohol use concurrently with treatment for liver disease. We will also discuss the importance of identifying and reducing stigma associated with alcohol related liver disease.
    • Shifting the Treatment Paradigm for Endocarditis Among People Who Use Drugs: Treat the Person, Not Just the Infection
      Drug use-associated IE (DUA-IE) now accounts for 1 in 10 hospitalizations endocarditis with an inpatient mortality rate between 5-8% and up to 26% in the year following discharge. At this rate, nearly 300,000 Americans will die of DUE-IE between 2020 and 2030. There is an urgent need to address the growing burden of DUA-IE in the U.S. To do so, providers must shift the treatment paradigm from a "do as I say" approach to a patient-focused "what do you need?" approach. Individuals with DUA-IE require more than just intravenous antibiotics. In this session, we will explore treatment paradigms that treat the person, not just the infection, to improve clinical outcomes and quality of life.
    • One Size Does Not Fit All: HCV Care in Various Settings
      Hepatitis C virus (HCV) infection is the leading cause of infectious disease death in the US. Despite the availability of effective oral direct acting agents (DAA) of short duration (2-3months) which have minimal side effects and cure HCV in over 95% of people who take these medications, treatment uptake among people who use drugs remains low. This session will review the current simplified approach to HCV screening and treatment as a prelude to a discussion of barriers to HCV treatment uptake among people who use drugs and strategies with proven effectiveness to increase HCV treatment uptake. These strategies will focus on integrated care, low threshold and peer supported approaches
    • Meeting People Where They are: Integrating Wound Care with Addiction Services
      In this talk we will review the impact of and risk factors for skin and soft tissue infections (SSTIs) among people who inject drugs (PWID), as well as barriers to healthcare and benefits of integrating wound care into addiction services. We will describe a model of integrated street medicine services for people who use drugs located in Baltimore, and successes and challenges with providing wound care in this model. We will review basic clinical wound care for PWID, with a focus on outpatient care and counseling for patients in SSTI prevention and wound care.

    These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:

    • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
    • Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
    • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine

    This conference addresses all 6 ACGME Competencies.

    Learning Objectives

    At the end of the course, learners should be able to:

    1. Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
    2. Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
    3. Develop practical applications for integrating new and emerging science into practice.
    4. Identify gaps in the field of addiction medicine that future research can address.
    5. Create a network of colleagues and resources to support the learner's practice or form future research collaborations.

    Registration Rates

    ASAM Learner TypeRate
    ASAM Member$29
    Non-Member$39
    Associate Member$19
    Resident Member*$19
    Student Member*$19

    *Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

    Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

    Refunds & Cancellations

    All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

    Registration Deadline: 10/1/2025

    Instructions

    1. Click on the Contents tab to begin this activity.
    2. Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
    3. Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
    4. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.

    Need Assistance?

    For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

    ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

    Michael Fingerhood, MD FACP DFASAM (Moderator)

    Associate Professor of Medicine and Public Health

    Johns Hopkins University

    Dr. Michael Fingerhood is an Associate Professor of Medicine and Public Health at the Johns Hopkins University. He is the Chief of the Division of Chemical Dependence and medical director of the Comprehensive Care Practice (CCP) at Johns Hopkins Bayview Medical Center. The CCP integrates substance use disorder treatment with primary medical care, including care for HIV and hepatitis C.

    No Relevant Financial Disclosures

    Geetanjali Chander, MD, MPH

    Professor

    University of Washington

    Geetanjali Chander, MD MPH is a Professor of Medicine at the University of Washington School of Medicine where is is the Division Head of General Internal Medicine..A general internist, her clinical work and research sit at the intersection of substance use and chronic disease. She is involved in clinical trials and implementation studies focused on integrating treatment for unhealthy alcohol use and alcohol use disorder into HIV and TB treatment, and among patients post liver transplant for alcohol related liver disease.

    No Relevant Financial Disclosures

    Joshua Barocas, MD

    Associate Professor of Medicine

    University of Colorado School of Medicine

    Joshua Barocas, MD is an Associate Professor of Medicine at the University of Colorado School of Medicine. He received his medical degree from the George Washington University School of Medicine and Public Health. He completed his Internal Medicine residency and was subsequently Chief Resident at the University of Wisconsin Hospitals and Clinics. Dr. Barocas completed a fellowship in Infectious Diseases at Massachusetts General Hospital and Brigham and Women’s Hospital in Boston.

    He leads an interdisciplinary research program that is specifically aimed at the goal of improving health outcomes for patients with infectious diseases including HIV and HCV, substance use disorders, and other vulnerable populations. His research, which uses clinical epidemiology, health economics, simulation modeling, and cost-effectiveness, informs clinical-decision making and health policy to answer clinically- and policy-relevant questions. He is engaged in research using these innovative methods to help understand the impact of and improve upon policies that affect people who use drugs infected with or at high risk for HIV and viral hepatitis. His research has been funded by NIDA, NIAID, and the MGH Executive Committee on Research Fund for Medical Discovery. He currently serves as Director of the Health Economics Core for the Massachusetts HEALing Communities Study, an NIH-funded grant to reduce overdose. He has been the recipient of several research awards including a NIDA Avenir Award (DP2), a NIDA Career Development Award (K01), the Charles A. King Trust Research Award, and the AAMC Herbert W. Nickens Faculty Fellowship Award. He has published over 70 peer-reviewed articles and editorials, including in leading journals such as NEJM, JAMA Internal Medicine, AJPH, Addiction, Clinical Infectious Diseases, and Annals of Internal Medicine. He has been widely cited in the media, including the New York Times, U.S. News and World Report, and NPR.

    Oluwaseun Falade-Nwulia

    MBBS, MPH

    Oluwaseun Falade-Nwulia, MBBS, MPH, is an Assistant Professor in the Division of Infectious Diseases at the Johns Hopkins University School of Medicine.She focuses her clinical pursuits on care of HIV and HCV infected patients and educating clinicians and public health practitioners about STDs, HIV, and hepatitis. Her research focuses on understanding the distribution and impact of highly active antiretroviral therapy on hepatitis B and C outcomes, and on improving HIV and hepatitis C (HCV) testing and access to care in medically underserved communities.

    Does Disclose- Abbvie Inc, Research grants paid to my institutions Hepatitis C; Gilead Fees paid for advisory services hepatitis B; Evon Medics co founder of company developing therapies for Substance use disorder treatment

    Amanda Rosecrans, MD, MHS

    Clinical Chief for Chronic Care and Mobile Clinical Services; Assistant Professor

    Baltimore City Health Department; Johns Hopkins University School of Medicine, Division of Infectious Diseases

    Dr. Amanda Rosecrans, MD, MHS, is the Clinical Chief of Chronic Care and Mobile Clinical Services at the Baltimore City Health Department (BCHD) and an Assistant Professor at the Johns Hopkins University School of Medicine, Division of Infectious Diseases. As a general internist with a particular interest the intersection of infectious diseases and addiction, she helped to develop and implement Healthcare on the Spot (The Spot), a mobile integrated street-medicine program that provides buprenorphine management and infectious disease services.

    No Relevant Financial Disclosures

    ACCME Accredited with Commendation

    CME, CE, CEU and Other Credit Types

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals
    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)
    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)
    This educational program is approved by CADTP: #205

    California Consortium of Addiction Programs and Professionals (CCAPP)
    This educational program is approved by CCAPP: #OS-20-330-1222

    Continuing Education Credits (CEUs)
    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC) / Continuing Certification Program (CCP)

    The ASAM State of the Art Course  meets the CME requirements for the following primary boards:
    • American Board of Medical Specialties (ABMS)
    • American Board of Preventive Medicine (ABPM)
    • American Board of Anesthesiology (ABA)
    • American Board of Pediatrics (ABP)
    • American Board of Internal Medicine (ABIM)
    • American Board of Surgery (ABS)
    • American Board of Psychiatry and Neurology (ABPN)
    • American Board of Addiction Medicine (ABAM)
    • Royal College of Physicians and Surgeons of Canada (RCPSC

    Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include mitigating all possible relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee member and Presenters have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

  • Product not yet rated Contains 9 Component(s), Includes Credits

    This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course examines research on Cognitive Behavioral Therapy for Insomnia (CBT.i), Alcoholics Anonymous (AA) and clinician-facilitated AA ("Twelve-Step Facilitation", TSF), the Common Elements Treatment Approach (CETA), and Contingency Management (CM). Presentations will provide essential information for clinicians working in non-specialty settings who may wish to utilize proven strategies.

    image

    New Evidence for Non-Pharmacological Treatment

    Recorded: Thursday, September 29, 2022 - Saturday, October 1, 2022
    On-Demand Session

    Overview

    This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course examines research on Cognitive Behavioral Therapy for Insomnia (CBT.i), Alcoholics Anonymous (AA) and clinician-facilitated AA (Twelve-Step Facilitation, TSF), the Common Elements Treatment Approach (CETA), and Contingency Management (CM). Presentations will provide essential information for clinicians working in non-specialty settings who may wish to utilize proven strategies.
    In addition to pharmacological treatment, addiction providers should have a robust toolbelt of non-pharmacological treatment approaches. Presentations in This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course examines research on Cognitive Behavioral Therapy for Insomnia (CBT.i), Alcoholics Anonymous (AA) and clinician-facilitated AA (Twelve-Step Facilitation, TSF), the Common Elements Treatment Approach (CETA), and Contingency Management (CM). Presentations will provide essential information for clinicians working in non-specialty settings who have little knowledge of, or experience with these non-pharmacological approaches but who may wish to utilize proven strategies. Following the session, a moderated panel discussion among the presenters answers audience questions.

    This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.

    • The Role of Sleep Treatment in Addiction Medicine
      The average human adult will spend one-third of their life asleep. It is essential for human health. Yet 1 in 3 to 4 adults in the United States will experience insomnia at some point in their lives, and rates are even higher among those who drink alcohol. This session reviews multidimensional conceptualizations of sleep health, the prevalence of sleep disorders across the spectrum of Alcohol Use Disorder, and the feasibility and efficacy of insomnia treatment in reducing alcohol use outcomes.
    • Twelve Step Facilitation: An Update
      Twelve Step Facilitation (TSF) is an evidence based treatment developed in the early 90's, which developed methods for clinicians to utilize to help patients to attend and benefit from attending 12 Step meetings ( specifically Alcoholics Anonymous (AA) - but can be used for other Anonymous programs). Just as a clinician might utilize Motivational Interviewing or CBT strategies within a session, A recent Cochrane review concluded that TSF was just as effective as these interventions, and in fact more effective in patients attaining abstinence from substances. There are over 60,000 AA groups a week in the USA. This presentation will demonstrate a few simple and brief methods for TSF which can be easily incorporated into clinicians sessions.
    • The CETA System of Care: An Innovative Way to Improve Behavioral/Mental Health Care
      The Common Elements System of Care Approach (www.cetaglobal.org) is an innovative approach to solving some of the challenges within mental and behavioral health care, such as long wait lists, frequent referrals, long treatment time, and ineffective care. It incorporates evidence-based assessment and triage, a range of clinical services, and monitoring and evaluation. It is designed to address comorbidity (inclusive of substance use and interpersonal violence), a wide range of severities, and work across the lifespan. This presentation will present evidence for the effectiveness of the CETA system, as well as walk through why mental/behavioral health needs innovation and change to progress.
    • Update on Contingency Management Research and Practice
      The rise of methamphetamine use across the US and the recent regulatory changes by the federal government have led to increased interest in contingency management. Further, research advances include increased evidence for contingency management as an intervention for alcohol use disorder, demonstrations that adapted versions of contingency management are effective for minorities groups, as well as initial research on the science of dissemination and implementation of the intervention in practice settings. This talk will provide an overview of contingency management, recent advancements in contingency management research, and federal policy changes that for the first time provide clear guidance on how contingency management can be used to treat substance use disorders with Medicaid and Medicare enrollees.

    These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:

    • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
    • Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
    • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine

    This conference addresses all 6 ACGME Competencies.

    Learning Objectives

    At the end of the course, learners should be able to:

    1. Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
    2. Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
    3. Develop practical applications for integrating new and emerging science into practice.
    4. Identify gaps in the field of addiction medicine that future research can address.
    5. Create a network of colleagues and resources to support the learner's practice or form future research collaborations.

    Registration Rates

    ASAM Learner TypeRate
    ASAM Member$29
    Non-Member$39
    Associate Member$19
    Resident Member*$19
    Student Member*$19

    *Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

    Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

    Refunds & Cancellations

    All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

    Registration Deadline: 10/1/2025

    Instructions

    1. Click on the Contents tab to begin this activity.
    2. Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
    3. Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
    4. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.

    Need Assistance?

    For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

    ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

    Michael Fingerhood, MD FACP DFASAM (Moderator)

    Associate Professor of Medicine and Public Health

    Johns Hopkins University

    Dr. Michael Fingerhood is an Associate Professor of Medicine and Public Health at the Johns Hopkins University. He is the Chief of the Division of Chemical Dependence and medical director of the Comprehensive Care Practice (CCP) at Johns Hopkins Bayview Medical Center. The CCP integrates substance use disorder treatment with primary medical care, including care for HIV and hepatitis C.

    No Relevant Financial Disclosures

    Mary Miller, PhD

    Assistant Professor

    University of Missouri

    Mary Beth Miller, Ph.D. is a clinical psychologist and Assistant Professor at the University of Missouri. Her research aims to enhance understanding of the etiology of substance use disorders in order to improve the effectiveness and efficiency of treatment. She is particularly interested in the interplay of substance use and sleep disorders and the process by which personalized feedback on one’s health and behaviors may facilitate behavior change. Current research in her lab focuses on insomnia treatment as a mechanism for improvement in alcohol use disorders.

    No Relevant Financial Disclosures

    Richard K. Ries

    MD, DFASAM

    Richard K. Ries, MD, is Professor of Psychiatry, and Director of the Addictions Division in the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine in Seattle, Washington and Director of the Addiction Treatment services at Harborview Medical Center in downtown Seattle. Dr. Ries received his undergraduate degree from Stanford, medical degree from Northwestern Medical School and completed his psychiatric residency at the University of Washington, Seattle, where he was Chief Resident. 

    Dr. Ries is board-certified in Psychiatry by the American Board of Psychiatry and Neurology with Added Qualifications in Addiction Psychiatry, and the American Board of Addiction Medicine.  A Distinguished Fellow of the American Psychiatric Association and a Fellow of the American Society of Addiction Medicine, he is on the editorial board and a reviewer for several scientific journals and holds a number of research grants from the National Institute of Health. 

    He has published numerous articles and abstracts on topics related to treatment of persons with severe mental illness, with special emphasis on those with co-existing problems with alcohol or drugs, and was the chair and co-chair of TIPS 9 and 42 on Treatment of Persons with Co-occurring  Addiction and Mental Disorders published by the national Center of Substance Abuse Treatment (CSAT).  He is senior editor of  the key reference text:  Principles of Addiction Medicine (edition V, 2014), published by the American Society of Addiction Medicine, and a noted expert in the  field of Addictions.

    No Relevant Financial Disclosures

    Laura Murray, MA, PhD

    Senior Scientist

    Johns Hopkins Bloomberg School of Public Health

    Laura Murray, MA, PhD; Senior Scientist, Clinical Psychologist; Johns Hopkins Bloomberg School of Public Health

    Dr. Murray is on faculty in the Departments of Mental Health and International Health. She has extensive expertise in a wide range of evidence-based treatments for mental and behavioral problems. Her research ranges from qualitatively understanding mental/behavioral health, to full randomized trials of treatments all over the world. She is a developer of the Common Elements Treatment Approach (www.cetaglobal.org), and has completed trials on this approach in Zambia, Colombia, Ukraine, Iraq and Thailand. Dr. Murray has a passion for innovating new solutions to improve service quality and delivery in mental/behavioral health care. Dr. Murray publishes extensively in top journals, trains globally, regularly speaks at conferences and organizations, and consults with organizations to improve functioning through skills training on stress, resiliency and leadership.

    Does Disclose: I am presenting as part of Johns Hopkins and the research conducted within that role. I disclose that I am the founder of CETA Global Inc. which gives me intellectual property rights to the CETA manual. This is an early stage developed in 2022 so there has been no financial benefit. The purpose of CETA Global is to be able to offer the CETA system more widely and easily outside of academia when there is not rigorous research involved.

    Michael McDonell, PhD

    Professor

    Washington State University

    Dr. Michael McDonell is a Professor in the Elson S. Floyd College of Medicine and the Director of the Promoting Research Initiatives in Substance Use and Mental Health (PRISM) Collaborative at Washington State University. He is a clinical psychologist with over 20 years of experience developing, testing, and implementing strength-based interventions for people with addiction and mental illness in community settings. He has led multiple National Institutes of Health funded studies demonstrating that contingency management can be used to reduce alcohol and drug use in individuals living with co-occurring serious mental illness. He also lead two studies demonstrating that culturally-adapted contingency management interventions are feasible and effective tools for addressing substance use disorders in American Indian and Alaska Native communities. He is currently involved in efforts to disseminate contingency management. This involved state-wide efforts to disseminate contingency management in Montana, Washington, and California, as well as similar efforts to providing training and technical support to Native communities.

    No Relevant Financial Disclosures

    ACCME Accredited with Commendation

    CME, CE, CEU and Other Credit Types

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals
    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)
    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)
    This educational program is approved by CADTP: #205

    California Consortium of Addiction Programs and Professionals (CCAPP)
    This educational program is approved by CCAPP: #OS-20-330-1222

    Continuing Education Credits (CEUs)
    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC) / Continuing Certification Program (CCP)

    The ASAM State of the Art Course  meets the CME requirements for the following primary boards:
    • American Board of Medical Specialties (ABMS)
    • American Board of Preventive Medicine (ABPM)
    • American Board of Anesthesiology (ABA)
    • American Board of Pediatrics (ABP)
    • American Board of Internal Medicine (ABIM)
    • American Board of Surgery (ABS)
    • American Board of Psychiatry and Neurology (ABPN)
    • American Board of Addiction Medicine (ABAM)
    • Royal College of Physicians and Surgeons of Canada (RCPSC

    Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include mitigating all possible relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee member and Presenters have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

  • Product not yet rated Contains 8 Component(s), Includes Credits

    This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course outlines addiction related disparities and promising treatment approaches for four different populations, including rural and socioeconomically deprived, Latino, immigrant, and transgender populations.

    image

    Addressing Treatment Disparities

    Recorded: Thursday, September 29, 2022 - Saturday, October 1, 2022
    On-Demand Session

    Overview

    This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course outlines addiction related disparities and promising treatment approaches for four different populations, including rural and socioeconomically deprived, Latino, immigrant, and transgender populations.
    There is an urgent need to address health disparities related to addiction among certain marginalized populations. These disparities are a result of individual, interpersonal, organizational, community and policy factors that both increase a population's risk of addiction as well as cause barriers for them to access addiction treatment. The presentations in this 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course outlines addiction related disparities and promising treatment approaches for four different populations, including rural and socioeconomically deprived, Latino, immigrant, and transgender populations. Following each presentation, presenters answer audience questions.

    This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.

    • Urban/Rural/Racial Disparities in Access to Buprenorphine and Opioid Treatment Programs
      This presentation demonstrates disparities in access to opioid treatment programs and buprenorphine providers for the treatment of opioid use disorder and associations between access to treatment, deprivation, and rurality and treatment outcomes. Geospatial analyses were conducted at the level of block groups (600-3000 people), the smallest spatial unit for which the U.S. Census Bureau provides sociodemographic data. Compared to metropolitan block groups, access to treatment was lower in micropolitan, small town, rural, and more socioeconomically deprived areas. American Indian/Alaska Native majority block groups had lower access to treatment compared to white or other racial/ethnic majority block groups. Analysis of barriers to access is necessary to devising initiatives to enhance access to treatment for the treatment of opioid use disorders.
    • Screening and Intervening on Structural Determinants of Health for Minoritized Individuals in Addiction Medicine 
      There is an urgent need for health disparities research to reduce the disproportionate burden of negative consequences related to alcohol use among socially disadvantaged Latinos compared to other racial/ethnic groups. Cultural adaptation of evidence-based treatments, such as motivational interviewing (MI), can improve access and overall response to alcohol treatment. However, research progress has been hindered by the few theoretically-guided tests of adaptation and limited knowledge about the active ingredients and mechanisms of behavior change that might discriminate an adapted, compared to non-adapted, intervention. This presentation will examine novel mechanisms of culturally adapted MI (CAMI), including decreases in perceived acculturation stress and reduced depression and anxiety, that may improve understanding of the stress-health behavior link observed among health disparities populations and how MI can be used to disrupt this association.  
    • ¿Cómo se dice Affordable Care? Immigrant health, access to care, and COVID-19
      The health and human dignity of undocumented immigrants (and others with tenuous legal residency status) and their families are frequently challenged by immigration integration policies and enforcement activities. In the US, undocumented immigrants are systematically excluded from the health system. In this session, we will discuss immigrant status as a social determinant of health, and the impact of immigration policy on health equity and public health, with special focus on mental health, substance use, and the COVID-19 pandemic.
    • Health Disparities among Transgender Women
      Transgender women in the US demonstrate numerous detrimental individual and structural health disparities, which impede their access to and engagement in HIV care and substance use services. These include disproportionate rates of individual-level health disparities such as lack of perceived support, cycles of incarceration, and untreated or undertreated substance use and mental health disorders, which are highly comorbid. Structural determinants of health include poverty and housing instability, lack of access to health insurance, transphobic stigma and discrimination, including transphobic stigma and discrimination specifically from healthcare providers. SUD is a demonstrated barrier to HIV care and behavioral health outcomes including poor linkage to care, ART nonadherence, increased high-cost emergency department visits, engagement in the street economy, and cycles of incarceration.

    These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:

    • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
    • Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
    • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine

    This conference addresses all 6 ACGME Competencies.

    Learning Objectives

    At the end of the course, learners should be able to:

    1. Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
    2. Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
    3. Develop practical applications for integrating new and emerging science into practice.
    4. Identify gaps in the field of addiction medicine that future research can address.
    5. Create a network of colleagues and resources to support the learner's practice or form future research collaborations.

    Registration Rates

    ASAM Learner TypeRate
    ASAM Member$29
    Non-Member$39
    Associate Member$19
    Resident Member*$19
    Student Member*$19

    *Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

    Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

    Refunds & Cancellations

    All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

    Registration Deadline: 10/1/2025

    Instructions

    1. Click on the Contents tab to begin this activity.
    2. Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
    3. Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
    4. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.

    Need Assistance?

    For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

    ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

    Kathleen Page, MD (Moderator)

    Associate Professor

    Johns Hopkins University School of Medicine

    Dr. Kathleen Page, MD, is an Associate Professor in the Division of Infectious Diseases at Johns Hopkins University School of Medicine. Her work focuses on improving access and quality of care to underserved communities. She co-founded Centro SOL to meet the health needs of Latino migrants through research, education, advocacy, and clinical care. She is the Medical Director of The Johns Hopkins Access Partnership which provides care to uninsured patients with financial need. Her research focuses on migrant health, health disparities and implementation science.

    No Relevant Financial Disclosures

    Solmaz Amiri, PhD

    Research Assistant Professor

    Washington State University

    Solmaz Amiri, PhD, Research Assistant Professor, Institute for Research and Education to Advance Community Health (IREACH), Elson S. Floyd College of Medicine, Washington State University

    Dr. Amiri is a Research Assistant Professor at the Elson S. Floyd College of Medicine and a core investigator with the Institute for Research and Education to Advance Community Health (IREACH) at Washington State University. She applies spatial analysis and quantitative techniques to study social, physical, and environmental factors associated with morbidity and mortality of chronic conditions. She has examined disparities in access to substance use treatment programs and the extent to which disparities in access are related to substance use treatment outcomes.

    No Relevant Financial Disclosures

    Christina Lee, PhD

    Associate Professor

    Boston University

    Christina S. Lee, Ph.D., is a licensed psychologist and an associate professor in the School of Social Work at Boston University (BUSSW). Dr. Lee is the Research Core Director at BU's Center for Innovation in Social Work and Health and a faculty affiliate at BU’s Center for Antiracist Research. She completed NIH funded pre and postdoctoral studies at the Center for Alcohol and Addiction Studies, Brown University, where she is now on the Training Faculty. Her research bridges the areas of intervention science, addiction psychology, and health disparities. By focusing on the effects of social and environmental stressors, Dr. Lee has become an influential voice in efforts to reduce risky health behaviors among diverse, understudied groups. She is PI and co-PI on NIH funded addiction treatment research and mentors graduate and postdoctoral scholars from diverse racial-ethnic groups. Dr. Lee is a member of the editorial board of the Journal of Consulting and Clinical Psychology and a member the Motivational Interviewing Network of Trainers, Diversity Committees in the Society of Addiction Psychology, American Psychological Association and the Research Society on Alcoholism.

    No Relevant Financial Disclosures

    Cathy Reback, PhD

    Senior Research Scientist

    Friends Research Institute

    Cathy J. Reback, PhD, is a Senior Research Scientist with Friends Research Institute and the Director of the Combination Prevention Core for the UCLA Center for HIV Identification, Prevention and Treatment Services. Dr. Reback is the Founder and Executive Director of Friends Community Center the community-based site for Friends Research Institute, which provides publically funded, culturally responsive, substance use and HIV prevention services for sexual and gender minority individuals. The focus of Dr. Reback’s research is an examination of the intersection of substance use disorders and HIV risk behaviors among sexual and gender minority individuals in community settings. Dr. Reback has an extensive background in conducting community-research collaborations, managing large-scale HIV prevention and intervention programs, designing and implementing technology-based and mHealth interventions, designing and implementing venue- and street-based intervention programs, evaluating behavioral and biomedical treatment therapies for populations with substance use and mental health disorders, and conducting mixed methods research studies. Additionally, in collaboration with several community-based organizations, she has used implementation science methodology to adopt, tailor, and transfer evidenced-based interventions into public health and community settings. Dr. Reback’s community and policy work includes current and past membership on numerous local and national HIV/AIDS and substance use task forces and advisory committees.

    No Relevant Financial Disclosures

    ACCME Accredited with Commendation

    CME, CE, CEU and Other Credit Types

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals
    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)
    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)
    This educational program is approved by CADTP: #205

    California Consortium of Addiction Programs and Professionals (CCAPP)
    This educational program is approved by CCAPP: #OS-20-330-1222

    Continuing Education Credits (CEUs)
    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC) / Continuing Certification Program (CCP)

    The ASAM State of the Art Course  meets the CME requirements for the following primary boards:
    • American Board of Medical Specialties (ABMS)
    • American Board of Preventive Medicine (ABPM)
    • American Board of Anesthesiology (ABA)
    • American Board of Pediatrics (ABP)
    • American Board of Internal Medicine (ABIM)
    • American Board of Surgery (ABS)
    • American Board of Psychiatry and Neurology (ABPN)
    • American Board of Addiction Medicine (ABAM)
    • Royal College of Physicians and Surgeons of Canada (RCPSC

    Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include mitigating all possible relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee member and Presenters have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

  • Product not yet rated Contains 8 Component(s), Includes Credits

    This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course highlights the latest research and emerging topics on stimulants and synthetic drugs, including the stimulant and fentanyl overdose mortality epidemic, synthetic stimulants and opioids, psychophysiological phenotyping of reward processing, and promising treatment approaches for Methamphetamine Use Disorder.

    image

    Stimulants and Synthetic Drugs

    Recorded: Thursday, September 29, 2022 - Saturday, October 1, 2022
    On-Demand Session

    Overview

    This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course highlights the latest research and emerging topics on stimulants and synthetic drugs, including the stimulant and fentanyl overdose mortality epidemic, synthetic stimulants and opioids, psychophysiological phenotyping of reward processing, and promising treatment approaches for Methamphetamine Use Disorder.
    According to the CDC, from 2012 through 2020 in the United States, the number of deaths involving methamphetamine increased more than 6-fold while the number of deaths involving cocaine more than tripled. These numbers have continued to rise since the beginning of the COVID-19 pandemic. Presentations in This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course highlights the latest research and emerging topics on stimulants and synthetic drugs, including the stimulant and fentanyl overdose mortality epidemic, synthetic stimulants and opioids, psychophysiological phenotyping of reward processing, and promising treatment approaches for Methamphetamine Use Disorder. Following each presentation, presenters answer audience questions.

    This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.

    • Colluding Crises: Understanding Stimulant and Fentanyl Overdose Mortality
      As fentanyl overdose mortality has climbed precipitously across the United States, rising deaths due to stimulant (cocaine or methamphetamine) toxicity have followed. The interaction between these two crises runs deep and is poorly understood, with a very limited understanding of the causes of death from acute stimulant toxicity, an unclear relationship between stimulant and fentanyl use, and uncertain interactions resulting in overdose death. We will review the trends in overdose death due to stimulants, fentanyl, and the two in combination; the clinical presentation of acute toxicity from stimulants and fentanyl; and existing data elucidating the co-use and toxicity from these drugs. Finally, we will address potential interventions to address the related overdose crisis.
    • Psychophysioloigcal phenotyping of reward processing and its modulation with abstinence in cocaine addiction
      The goal of the presentation is to discuss motivational dysregulation, or deficits in reward processing, in substance use disorders and to discuss how these processes change during abstinence. Different aspects of reward processing (e.g., drug-related and non-drug-related) will be defined. Electroencephalography (EEG) technique will be introduced that can be used to objectively assess motivational dysregulation in substance use disorder. To make the case for clinical relevance and significance of this topic, several studies from the presenter's and other research groups on this topic will be presented. The presentation will conclude with a discussion on other brain imaging techniques for studying motivational dysregulation and how such work provides bases for the development of treatments and interventions for substance use disorders.
    • Pharmacology of New Synthetic Stimulants and Opioids Appearing in Clandestine Drug Markets
      New psychoactive substances (NPS) are synthetic drugs specifically engineered to bypass current drug control laws. This presentation will provide up-to-date information about the stimulant and opioid NPS that are emerging in clandestine drug markets in the US and elsewhere. The chemical structures, molecular mechanisms of drug action, and preclinical pharmacology for representative stimulant (e.g., eutylone) and opioid (e.g., isotonitazene) NPS will be presented. Clinical symptomatology produced by the drugs will be described. The information provided will be utilized to assess harms, and guide strategies for management and treatment.
    • Treatment of Methamphetamine Use Disorder Using Injectable Naltrexone and Oral Bupropion
      Methamphetamine use continues to increase and has now been characterized as the ?fourth wave? of the opioid epidemic. Furthermore, the majority of overdose deaths now involve stimulants. Despite the acknowledgement of this public health crisis, there are no FDA approved treatments for methamphetamine use disorder. This presentation will address this urgency by reviewing outcomes from a recent novel clinical trial which evaluates the efficacy and safety of the combination of extended-release oral bupropion and extended-release injectable naltrexone for the treatment of methamphetamine use disorder.

    These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:

    • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
    • Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
    • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine

    This conference addresses all 6 ACGME Competencies.

    Learning Objectives

    At the end of the course, learners should be able to:

    1. Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
    2. Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
    3. Develop practical applications for integrating new and emerging science into practice.
    4. Identify gaps in the field of addiction medicine that future research can address.
    5. Create a network of colleagues and resources to support the learner's practice or form future research collaborations.

    Registration Rates

    ASAM Learner TypeRate
    ASAM Member$29
    Non-Member$39
    Associate Member$19
    Resident Member*$19
    Student Member*$19

    *Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

    Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

    Refunds & Cancellations

    All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

    Registration Deadline: 10/1/2025

    Instructions

    1. Click on the Contents tab to begin this activity.
    2. Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
    3. Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
    4. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.

    Need Assistance?

    For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

    ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

    Kathleen Page, MD (Moderator)

    Associate Professor

    Johns Hopkins University School of Medicine

    Dr. Kathleen Page, MD, is an Associate Professor in the Division of Infectious Diseases at Johns Hopkins University School of Medicine. Her work focuses on improving access and quality of care to underserved communities. She co-founded Centro SOL to meet the health needs of Latino migrants through research, education, advocacy, and clinical care. She is the Medical Director of The Johns Hopkins Access Partnership which provides care to uninsured patients with financial need. Her research focuses on migrant health, health disparities and implementation science.

    No Relevant Financial Disclosures

    Phillip O. Coffin, MD, MIA, FACP, FIDSA

    Director of Substance Use Research

    San Francisco Dept of Public Health

    Phillip Coffin, MD, MIA, is a board-certified, practicing internist, infectious disease, and addiction medicine specialist, including inpatient and outpatient care. Dr. Coffin also directs the Center on Substance Use and Health, where he conducts and oversees clinical trials addressing therapies for substance use disorders and prevention or treatment of overdose, HIV, and viral hepatitis; observational studies addressing substance use and the shifting climate of opioid prescribing; local substance use epidemiology; and programmatic efforts to improve opioid management in clinical care.

    Does Disclose Gilead Sciences: NIH-funded trial of PrEP that receives donated TAF/(PrEP), Clinical Condition: HIV.

    Muhammad Parvaz, PhD

    Assistant Professor

    Icahn School of Medicine at Mount Sinai

    Dr. Muhammad A. Parvaz, PhD is an Assistant Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai. His primary research interest includes studying cognitive-affective interactions underlying deficits in motivation, reinforcement learning and inhibitory control in mental health disorders, specifically in substance use disorders, using behavioral, computational and neuroimaging techniques. As a cognitive neuroscientist with a background in biomedical engineering, he places special emphasis on understanding disease mechanisms with an eye towards developing clinically useful biomarkers to accelerate bench-to-bedside translation of lab-based assessments. Currently, his research involves tracking neurobehavioral plasticity during the onset of as well as remission from substance use disorders. At the clinical translation side of this work, his lab is developing and testing interventions for craving reduction using behavioral and neuromodulation techniques. In parallel, he is interested in studying the onset and development of aberrant cognitive-affective interaction in adolescents as well as risk factors that render some youth vulnerable to develop psychopathological phenotypes (e.g., substance use disorder, eating disorders and psychosis). For these studies, his lab uses a comprehensive multimodal approach with multiscale modeling of environmental (socio-economic factors), clinical (rating scales), behavioral (cognitive tasks), molecular (MR spectroscopy and blood based inflammatory markers), physiological (EEG) and circuit-level (fMRI) biomarkers to more precisely define the phenotype of interest and to track or predict individualized outcomes (e.g., development of substance use disorders in adolescents and relapse in treatment seeking addicted individuals).

    No Relevant Financial Disclosures

    Michael H. Baumann

    PhD

    Michael H. Baumann, PhD is a Staff Scientist and Chief of the Designer Drug Research Unit (DDRU), at the Intramural Research Program (IRP) of the National Institute on Drug Abuse (NIDA) in Baltimore, Maryland.  The DDRU collects, analyzes and disseminates the most up-to-date information about the pharmacology and toxicology of newly-emerging synthetic drugs of abuse (i.e., designer drugs), more formally known as new psychoactive substances (NPS).  Working with partner organizations such as the Drug Enforcement Administration (DEA) and the National Drug Early Warning System (NDEWS), Dr. Baumann is kept informed about trends in the misuse of NPS.  The DDRU has characterized the molecular mechanism of action and pharmacological effects for a diversity of NPS, including “bath salts” (synthetic stimulants), “spice” (synthetic cannabinoids) and synthetic opioids.  Findings from the DDRU inform law enforcement personnel, health care workers, clinical toxicologists, forensic scientists, basic researchers, and policymakers who are involved in responding to the global spread of NPS and the associated public health risks. 


    No Relevant Financial Disclosures

    Madhukar H. Trivedi

    MD

    Madhukar Trivedi is Professor of Psychiatry, Chief of the Division of Mood Disorders, and Director of the Center for Depression Research and Clinical Care at UT Southwestern Medical Center. He earned his MBBS and MS in Baroda, India, completing his residencies in Psychiatry at University General Hospital, Baroda, India and Henry Ford Hospital, Detroit, Michigan. He completed his fellowship at UT Southwestern, where he now serves as Betty Jo Hay Distinguished Chair in Mental Health and Julie K. Hersh Chair for Depression Research and Clinical Care. Certified by the American Board of Psychiatry and Neurology, Dr. Trivedi is an established clinical and translational researcher with extensive experience serving as PI and Co-PI on several single and multi-site clinical trials funded by NIH, foundations and industry sponsors.

    Dr. Trivedi’s research over the last 25 years has focused on understanding the neurobiology and psychology of depression and bipolar disorder, with a particular focus on developing an empirical basis for improving treatment of depression. Dr. Trivedi and his team have been involved in many of the pivotal studies involving the establishment of efficacy of antidepressant treatments (medications, psychotherapy, exercise, complimentary treatments, devices, etc.), examining next steps in treatment resistant depression to develop algorithms and guidelines, and developing and validating biomarkers in order to reach the goal of precision medicine for mood disorders. Among his most notable studies are the Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC) trial, Combining Medications to Enhance Depression Outcomes (CO-MED) trial, Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, and the Texas Resilience Against Depression (T-RAD) study.

    Does Disclose: Alkermes; monetary payment; Consulting Alto Neuroscience Inc; monetary payment & stock investments; Stockholder / Scientific Advisory Axsome Therapeutics, Inc.; N/A; Consulting Biogen MA Inc; monetary payment; Consulting Circular Genomics Inc.; stock investments; Consulting / Stockholder GH Research Limited; monetary payment; Consulting GreenLight VitalSign6; stock investments; Stockholder / Scientific Advisory Heading Health, Inc; n/a; Scientific Advisory; Janssen; n/a; Consulting Legion Health; stock investment; Stockholder / Scientific Advisory Mind Medicine (MindMed) Inc.; n/a; Consulting Neurocrine Biosciences Inc; n/a; Consulting Orexo US Inc; monetary payment; Consulting / Scientific Advisory Otsuka America Pharmaceutical, Inc.; monetary payment; Consulting Otsuka Canada Pharmaceutical Inc; monetary payment; Consulting Otsuka Pharmaceutical Development & Commercialization, Inc.; monetary payment; Consulting; Sage Therapeutics; monetary payment; Consulting Takeda Pharmaceutical Company Ltd.; n/a; Consutling WebMD; monetary payment; Consulting Sparian Biosciences; n/a; Consulting

    ACCME Accredited with Commendation

    CME, CE, CEU and Other Credit Types

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals
    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)
    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)
    This educational program is approved by CADTP: #205

    California Consortium of Addiction Programs and Professionals (CCAPP)
    This educational program is approved by CCAPP: #OS-20-330-1222

    Continuing Education Credits (CEUs)
    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC) / Continuing Certification Program (CCP)

    The ASAM State of the Art Course  meets the CME requirements for the following primary boards:
    • American Board of Medical Specialties (ABMS)
    • American Board of Preventive Medicine (ABPM)
    • American Board of Anesthesiology (ABA)
    • American Board of Pediatrics (ABP)
    • American Board of Internal Medicine (ABIM)
    • American Board of Surgery (ABS)
    • American Board of Psychiatry and Neurology (ABPN)
    • American Board of Addiction Medicine (ABAM)
    • Royal College of Physicians and Surgeons of Canada (RCPSC

    Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include mitigating all possible relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee member and Presenters have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

  • Contains 4 Component(s), Includes Credits

    This 1-hour, on-demand session from the 2022 ASAM State of the Art Course overviews emerging issues and advances in addiction medicine at SAMHSA, NIDA, and NIAAA.

    image

    Federal Agency Session: Special Addresses and Open Discussion

    Recorded: Thursday, September 29, 2022 - Saturday, October 1, 2022
    On-Demand Session

    Overview

    This 1-hour, on-demand session from the 2022 ASAM State of the Art Course overviews emerging issues and advances in addiction medicine at SAMHSA, NIDA, and NIAAA.
    During this 1-hour, on-demand session from the 2022 ASAM State of the Art Course, federal agency leaders from SAMHSA, NIDA, and NIAAA give brief overviews about emerging issues and advances in addiction medicine from their respective organizations. Following the presentations, State of the Art Planning Committee Chair, Dr. Michael I. Fingerhood leads the agencies in a lively discussion about the most pressing topics in addiction medicine.


    These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:

    • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
    • Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
    • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine

    This conference addresses all 6 ACGME Competencies.

    Learning Objectives

    At the end of the course, learners should be able to:

    1. Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
    2. Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
    3. Develop practical applications for integrating new and emerging science into practice.
    4. Identify gaps in the field of addiction medicine that future research can address.
    5. Create a network of colleagues and resources to support the learner's practice or form future research collaborations.

    Registration Rates

    ASAM Learner TypeRate
    ASAM Member$0
    Non-Member$0
    Associate Member$0
    Resident Member*$0
    Student Member*$0

    *Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

    Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

    Refunds & Cancellations

    All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

    Registration Deadline: 10/1/2025

    Instructions

    1. Click on the Contents tab to begin this activity.
    2. Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 2 out of 3 questions correctly.
    3. Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
    4. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.

    Need Assistance?

    For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

    ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

    Michael Fingerhood, MD FACP DFASAM (Moderator)

    Associate Professor of Medicine and Public Health

    Johns Hopkins University

    Dr. Michael Fingerhood is an Associate Professor of Medicine and Public Health at the Johns Hopkins University. He is the Chief of the Division of Chemical Dependence and medical director of the Comprehensive Care Practice (CCP) at Johns Hopkins Bayview Medical Center. The CCP integrates substance use disorder treatment with primary medical care, including care for HIV and hepatitis C.

    No Relevant Financial Disclosures

    Miriam Delphin-Rittmon, PhD

    Dr. Miriam E. Delphin-Rittmon is currently Assistant Secretary for Mental Health and Substance Use in the U.S. Department of Health and Human Services and the Administrator of the Substance Abuse and Mental Health Services Administration. She previously served as Commissioner of the Connecticut Department of Mental Health and Addiction Services (DMHAS) and served in this role for six years. Prior positions held at DMHAS include Deputy Commissioner, Senior Policy Advisor and Director of the department’s Office of Multicultural Healthcare Equity. In her role as Commissioner, Dr. Delphin-Rittmon was committed to promoting recovery oriented, integrated, and culturally responsive services and systems that foster dignity, respect, and meaningful community inclusion.
    Prior to her current appointment, Dr. Delphin-Rittmon was an Adjunct Associate Professor at Yale University where she served on faculty for the past 20 years. While at Yale Dr. Delphin-Rittmon served as the Director of Cultural Competence and Research Consultation with the Yale University Program for Recovery and Community Health.
    In May 2014, Dr. Delphin-Rittmon completed a two-year White House appointment working as a Senior Advisor to the Administrator of the Substance Abuse and Mental Health Services Administration (SAMHSA) with the U.S. Department of Health and Human Services. While at SAMHSA, she worked on a range of policy initiatives addressing behavioral health equity, workforce development, and healthcare reform.
    Through her 20 year career in the behavioral health field Dr. Delphin-Rittmon has extensive experience in the design, evaluation, and administration of mental health, substance use and prevention services and systems and has received several awards for advancing policy in these areas. Most recently, she received the 2019 State Service Award from the National Association of State Drug and Alcohol Directors and the 2016 Mental Health Award for Excellence from the United Nations Committee on Mental Health.
    She received her B.A. in Social Science from Hofstra University in 1989, her M.S. and Ph.D. in Clinical Psychology from Purdue University 1992 and 2001, respectively, and completed a postdoctoral fellowship in clinical community psychology at Yale University in 2002

    No Relevant Financial Disclosures

    Wilson Compton

    MD, MPE

    Wilson M. Compton, MD, MPE serves as the Deputy Director of the National Institute on Drug Abuse (NIDA) of the National Institutes of Health. In his current role, Dr. Compton's responsibilities include providing scientific leadership in the development, implementation, and management of NIDA's research portfolio and working with the Director to support and conduct research to improve the prevention and treatment of drug abuse and addiction. Prior to his current appointment, Dr. Compton served as the Director of NIDA's Division of Epidemiology, Services and Prevention Research from 2002 until 2013. In this leadership role, he oversaw the scientific direction of a complex public health research program of national and international scope addressing: 1) the extent and spread of drug abuse, 2) how to prevention drug abuse, and 3) how to implement drug abuse prevention and treatment services as effectively as possible. Before joining NIDA, Dr. Compton was Associate Professor of Psychiatry and Director of the Master in Psychiatric Epidemiology Program at Washington University in Saint Louis as well as Medical Director of Addiction Services at the Barnes-Jewish Hospital in Saint Louis. Dr. Compton received his undergraduate education from Amherst College. He attended medical school and completed his residency training in psychiatry at Washington University. During his career, Dr. Compton has achieved multiple scientific accomplishments: he was selected to serve as a member of the DSM-5 Revision Task Force; is the author of more than 130 articles and chapters; and is an invited speaker at multiple high-impact venues. Dr. Compton is the recipient of multiple awards and in 2008, he received the Senior Scholar Health Services Research Award from the American Psychiatric Association, in 2010 the Paul Hoch Award from the American Psychopathological Association, in both 2012 and 2013, he was selected to receive the Leveraging Collaboration Award from the Food and Drug Administration. In 2013, Dr. Compton received the prestigious Health and Human Services Secretary's Award for Meritorious Service.

    Does Disclose: 3M Companies: Ownership Interest includes stock, stock options, patent or other intellectual property; General Electric Co.: Ownership Interest includes stock, stock options, patent or other intellectual property Pfizer, Inc.: Ownership Interest includes stock, stock options, patent or other intellectual property.

    Aaron White, PhD

    Leader, Epidemiology and Biometry Branch and Senior Scientific Advisor to the Director

    National Institute on Alcohol Abuse and Alcoholism

    Aaron White is the Senior Scientific Advisor to the Director at the National Institute on Alcohol Abuse and Alcoholism (NIAAA). His areas of scientific expertise include the brain mechanisms and epidemiology of alcohol-induced memory blackouts, and the impact of alcohol and other drugs on brain function and behavior, particularly during the adolescent years.

    Dr. White co-wrote the online alcohol prevention course, AlcoholEdu, which has been completed by more than 3 million high school and college students to date. He joined NIAAA in 2008 and, until recently, was a Program Officer in the Division of Epidemiology and Prevention Research. As a Program Officer, Dr. White oversaw a large portfolio of grants covering epidemiology and prevention research related to underage and college drinking. In 2015, he was promoted to Senior Scientific Advisor to the Director, Dr. George Koob. In this position, Dr. White advises the Director regarding a wide variety of scientific topic areas in alcohol and other drug research.

    He also frequently takes part in media interviews and delivers presentations on behalf of the Institute, including presentations on addiction and overdoses at a meeting of the United Nations Office of Drugs and Crime in Austria last fall. He is an author on 37 peer-reviewed manuscripts, 22 review papers and book chapters, 3 books and has delivered several hundred presentations about alcohol and the brain.

    No Relevant Financial Disclosures

    ACCME Accredited with Commendation

    CME, CE, CEU and Other Credit Types

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals
    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)
    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)
    This educational program is approved by CADTP: #205

    California Consortium of Addiction Programs and Professionals (CCAPP)
    This educational program is approved by CCAPP: #OS-20-330-1222

    Continuing Education Credits (CEUs)
    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC) / Continuing Certification Program (CCP)

    The ASAM State of the Art Course  meets the CME requirements for the following primary boards:
    • American Board of Medical Specialties (ABMS)
    • American Board of Preventive Medicine (ABPM)
    • American Board of Anesthesiology (ABA)
    • American Board of Pediatrics (ABP)
    • American Board of Internal Medicine (ABIM)
    • American Board of Surgery (ABS)
    • American Board of Psychiatry and Neurology (ABPN)
    • American Board of Addiction Medicine (ABAM)
    • Royal College of Physicians and Surgeons of Canada (RCPSC

    Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include mitigating all possible relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee member and Presenters have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

  • Product not yet rated Contains 6 Component(s), Includes Credits

    This 1-hour, on-demand session from the 2022 ASAM State of the Art Course identifies new ways to treat, cure, and prevent addiction using advanced neuro-technologies.

    image

    New in Neurobiology

    Recorded: Thursday, September 29, 2022 - Saturday, October 1, 2022
    On-Demand Session

    Overview

    This 1-hour, on-demand session from the 2022 ASAM State of the Art Course identifies new ways to treat, cure, and prevent addiction using advanced neuro-technologies.
    Although addiction is widely understood to be a chronic brain disorder, the neurological basis and consequences of addiction remain poorly understood. The presentations in this 1-hour, on-demand session from the 2022 ASAM State of the Art Course identify new ways to treat, cure, and prevent addiction using advanced neuro-technologies. Following each presentation, presenters answer audience questions.

    This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.

    • Updates on the BRAIN Initiative
      Emerging from formative years, the NIH BRAIN Initiative has matured into a vibrant enterprise spanning a diverse field of researchers from the biological, engineering, and clinical sciences from across the United States and around the world. The rising trajectory of the BRAIN Initiative as a major force in neuroscience discovery presents a timely opportunity to invest in new large-scale projects that offer the potential to transform the field. The BRAIN Initiative is rolling out three transformative projects that will (1) build an atlas of cell types in the human brain, (2) develop a microconnectivity map of an entire mammalian brain, and (3) provide tools for precision access to the identified cell types. Together, these will enable the development of novel interventions for human circuit disorders.
    • Brain Mechanisms of Relapse Prevention Medications for Opioid Use Disorder
      Opioid use disorder (OUD) affects multiple neurocognitive domains. Non-invasive neuroimaging techniques, especially functional magnetic resonance imaging (fMRI), have shown great promise in elucidating the neural mechanisms of addiction in general and OUD in particular. The presentation will cover the key domains of OUD-related neurocognitive deficits such as abnormal incentive salience, poor executive control, aberrant emotional reactivity, impaired social cognition, and altered functional connectivity between brain regions. This will be followed by reviewing the fMRI results concerning effects of relapse prevention medications, including agonist and antagonist treatments, on the brain circuits affected by OUD. Lastly, the presentation will discuss the potential of advanced statistical and computational methodologies that may further our mechanistic understanding of OUD and its treatments.

    These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:

    • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
    • Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
    • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine

    This conference addresses all 6 ACGME Competencies.

    Learning Objectives

    At the end of the course, learners should be able to:

    1. Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
    2. Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
    3. Develop practical applications for integrating new and emerging science into practice.
    4. Identify gaps in the field of addiction medicine that future research can address.
    5. Create a network of colleagues and resources to support the learner's practice or form future research collaborations.

    Registration Rates

    ASAM Learner TypeRate
    ASAM Member$29
    Non-Member$39
    Associate Member$19
    Resident Member*$19
    Student Member*$19

    *Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

    Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

    Refunds & Cancellations

    All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

    Registration Deadline: 10/1/2025

    Instructions

    1. Click on the Contents tab to begin this activity.
    2. Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 2 out of 3 questions correctly.
    3. Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
    4. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.

    Need Assistance?

    For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

    ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

    Kathleen Page, MD (Moderator)

    Associate Professor

    Johns Hopkins University School of Medicine

    Dr. Kathleen Page, MD, is an Associate Professor in the Division of Infectious Diseases at Johns Hopkins University School of Medicine. Her work focuses on improving access and quality of care to underserved communities. She co-founded Centro SOL to meet the health needs of Latino migrants through research, education, advocacy, and clinical care. She is the Medical Director of The Johns Hopkins Access Partnership which provides care to uninsured patients with financial need. Her research focuses on migrant health, health disparities and implementation science.

    No Relevant Financial Disclosures

    John Ngai

    PhD

    John J. Ngai, Ph.D., is the Director of the NIH’s Brain Research through Advancing Innovative Neurotechnologies (BRAIN®) Initiative. Dr. Ngai earned his bachelor’s degree in chemistry and biology from Pomona College, Claremont, California, and Ph.D. in biology from the California Institute of Technology (Caltech) in Pasadena. He was a postdoctoral researcher at Caltech and at the Columbia University College of Physicians and Surgeons before starting his faculty position at the University of California at Berkeley. During more than 25 years as a Berkeley faculty member, Dr. Ngai has trained 20 undergraduate students, 24 graduate students and 15 postdoctoral fellows in addition to teaching well over 1,000 students in the classroom. 

    His work has led to the publication of more than 70 scientific articles in some of the field’s most prestigious journals and 10 U.S. and international patents. Dr. Ngai has received many awards including from the Sloan Foundation, Pew Charitable Trusts, and McKnight Endowment Fund for Neuroscience. As a faculty member, Dr. Ngai has served as the director of Berkeley’s Neuroscience Graduate Program and Helen Wills Neuroscience Institute. He has also provided extensive service on NIH study sections, councils and steering groups, including as previous co-chair of the NIH BRAIN® Initiative Cell Census Consortium Steering Group. Dr. Ngai will oversee the long-term strategy and day-to-day operations of the NIH BRAIN Initiative as it takes on the challenges of the next five year plan.

    No Relevant Financial Disclosures

    Zhenhao Shi, PhD

    Assistant Professor

    University of Pennsylvania

    Zhenhao Shi, PhD is an incoming Research Assistant Professor at the Department of Psychiatry at the University of Pennsylvania (UPenn). He received his BS in Psychology and PhD in Cognitive Neuroscience from Peking University in 2009 and 2014, respectively. He joined the UPenn Annenberg Public Policy Center as a postdoctoral fellow in 2014 and became a NIDA T32 fellow at the UPenn Department of Psychiatry in 2016. Dr. Shi’s research is focused on the neurocognitive mechanisms of addiction, with an emphasis on tobacco and opioid use disorders. Using behavioral, genetic and brain imaging methodologies, his work examined the neural, genetic and personality factors that contribute to the effectiveness of anti-smoking communications. He also investigated the predictive neural signatures of treatment outcomes in opioid use disorder and the neurobehavioral effects of opioid withdrawal and opioid antagonist treatment. Dr. Shi is currently the Principal Investigator of a NIDA K01 Award, which aims to establish multimodal neural prediction models for treatment outcomes in patients with opioid use disorder. He is also collaborating on a number of other scientific projects on alcohol use disorder and use of electronic cigarettes. Dr. Shi’s work has been recognized by a number of awards, including multiple scholarships, a Trainee Professional Development Award from the Society for Neuroscience, and a Travel Award for Early Career Investigators from the College on Problems of Drug Dependence.

    No Relevant Financial Disclosures

    ACCME Accredited with Commendation

    CME, CE, CEU and Other Credit Types

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals
    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)
    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)
    This educational program is approved by CADTP: #205

    California Consortium of Addiction Programs and Professionals (CCAPP)
    This educational program is approved by CCAPP: #OS-20-330-1222

    Continuing Education Credits (CEUs)
    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC) / Continuing Certification Program (CCP)

    The ASAM State of the Art Course  meets the CME requirements for the following primary boards:
    • American Board of Medical Specialties (ABMS)
    • American Board of Preventive Medicine (ABPM)
    • American Board of Anesthesiology (ABA)
    • American Board of Pediatrics (ABP)
    • American Board of Internal Medicine (ABIM)
    • American Board of Surgery (ABS)
    • American Board of Psychiatry and Neurology (ABPN)
    • American Board of Addiction Medicine (ABAM)
    • Royal College of Physicians and Surgeons of Canada (RCPSC

    Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include mitigating all possible relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee member and Presenters have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

  • Product not yet rated Contains 9 Component(s), Includes Credits

    This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course examines new research on Alcohol Use Disorder (AUD) treatment, including findings from a cutting-edge alcohol registry, evidence outlining the role of the endocrine system in addiction, and advances in the use of computational modeling and biomarkers to advance personalized medicine for AUD.

    image

    Alcohol Use Disorder: Pharmacotherapy and Recovery

    Recorded: Thursday, September 29, 2022 - Saturday, October 1, 2022
    On-Demand Session

    Overview

    This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course examines new research on Alcohol Use Disorder (AUD) treatment, including findings from a cutting-edge alcohol registry, evidence outlining the role of the endocrine system in addiction, and advances in the use of computational modeling and biomarkers to advance personalized medicine for AUD.
    Alcohol Use Disorder (AUD) is a heterogeneous disorder characterized by individual variation in clinical features, neurocognitive functioning, molecular pathways, and neural circuits making it challenging to treat. This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course examines new research on AUD treatment, including findings from a cutting-edge alcohol registry, evidence outlining the role of the endocrine system in addiction, and advances in the use of computational modeling and biomarkers to advance personalized medicine for AUD. Following the session, a moderated panel discussion among the presenters answers audience questions.

    This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.

    • Facilitating Recovery in the Context of Healthcare: Challenges and Opportunities
      This presentation describes an approach to facilitating recovery across the spectrum of alcohol problems, from unhealthy use through severe alcohol use disorders, in the context of healthcare delivery. We discuss the development, implementation and uses of an innovative, cutting-edge Alcohol Registry, a collaboration between Kaiser Permanente Northern California and the National Institute on Alcohol Abuse and Alcoholism. The data in the Alcohol Registry provides critical diagnostic, alcohol consumption quantity and frequency, demographic and services utilization information for conducting epidemiologic, health services and implementation science research and informs quality improvement efforts across the continuum of care, from primary care to specialty addiction medicine. We discuss systemic challenges to enabling recovery from alcohol problems in healthcare settings, and describe ways to enhance systems? approach to alcohol treatment.
    • Gut-Brain Axis and Neuroendocrinology: Translation to Addiction Medicine
      Endocrine signals from the periphery traditionally known to regulate homeostasis, fluid intake, appetite and food intake may play an important role in reward regulation as well as in development of alcohol and substance use disorders, therefore representing promising novel targets in medication development. Dr. Leggio on behalf of his research team and collaborators, will present recent translational preclinical and human data on systems related to the gut-brain axis and to neuroendocrine pathways. Examples include the ghrelin system, the glucagon-like peptide-1 (GLP-1) system and the aldosterone / mineralocorticoid receptor (MR) system. This line of research supports additional efforts aimed to investigate whether these neuroendocrine pathways may represent novel potential targets for medication development for addictions.
    • Beyond Treating Acute Alcohol Withdrawal: New Medications to Address Post-Withdrawal Relapse and Recovery
      Despite several approved medications to treat Alcohol Use Disorder (AUD), there are high relapse and treatment failure rates in AUD. Clinical presentation of treatment entering individuals with AUD indicates significant heterogeneity, with severity of illness and varying levels of alcohol withdrawal symptoms and craving impacting treatment course and outcome. Data on effects of moderate to high severity AUD, stress biology and associated poor treatment response will also be shown. Finally, results from a 12-week randomized clinical trial of Prazosin will be presented to show that its efficacy is moderated by alcohol withdrawal symptoms. The findings will be discussed in the context of the need for valid clinical, neural and biological markers to address AUD heterogeneity to improve relapse risk and treatment outcome in AUD.
    • Leveraging Systems Pharmacology to Advance Precision Medicine for Treatment of Alcohol Use Disorder
      There is an urgent need to personalize evidence-based treatments for alcohol use disorder (AUD). AUD is a heterogeneous disorder characterized by individual variation in clinical features, neurocognitive functioning, molecular pathways, and neural circuits. Advances will be presented in the use of computational modeling and biomarkers to advance personalized medicine for AUD by predicting likely responders to gabapentin, topiramate and other pharmacological treatments.

    These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:

    • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
    • Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
    • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine

    This conference addresses all 6 ACGME Competencies.

    Learning Objectives

    At the end of the course, learners should be able to:

    1. Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
    2. Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
    3. Develop practical applications for integrating new and emerging science into practice.
    4. Identify gaps in the field of addiction medicine that future research can address.
    5. Create a network of colleagues and resources to support the learner's practice or form future research collaborations.

    Registration Rates

    ASAM Learner TypeRate
    ASAM Member$29
    Non-Member$39
    Associate Member$19
    Resident Member*$19
    Student Member*$19

    *Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

    Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

    Refunds & Cancellations

    All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

    Registration Deadline: 10/1/2025

    Instructions

    1. Click on the Contents tab to begin this activity.
    2. Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
    3. Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
    4. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.

    Need Assistance?

    For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

    ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

    Kathleen Page, MD (Moderator)

    Associate Professor

    Johns Hopkins University School of Medicine

    Dr. Kathleen Page, MD, is an Associate Professor in the Division of Infectious Diseases at Johns Hopkins University School of Medicine. Her work focuses on improving access and quality of care to underserved communities. She co-founded Centro SOL to meet the health needs of Latino migrants through research, education, advocacy, and clinical care. She is the Medical Director of The Johns Hopkins Access Partnership which provides care to uninsured patients with financial need. Her research focuses on migrant health, health disparities and implementation science.

    No Relevant Financial Disclosures

    Stacy Sterling

    MPH, MSW

    Stacy Sterling, DrPH, MSW, MPH, is a senior research scientist with the Division of Research and co-directs its Center for Addiction and Mental Health Research. She is part of DOR's Drug and Alcohol Research Team (DART) and its Behavioral Health Research Initiative. Her research interests include developing systems for implementing evidence-based, integrated, behavioral health services into primary care, adolescent behavioral health prevention and early intervention, and alcohol and drug and mental health treatment outcomes and access. Dr. Sterling is a standing member of the National Institute of Alcohol Abuse and Addiction (NIAAA) Clinical, Treatment and Health Services Research study section. She is principal investigator of a study funded by the Conrad N. Hilton Foundation to develop predictive models for adolescent substance use problem development, and of studies funded by the Robert Wood Johnson Foundation and Center for Substance Abuse Treatment of adolescents in drug and alcohol treatment in Kaiser Permanente.

    She is the Kaiser Permanente Principal Investigator of multiple studies including: a trial funded by the Hilton Foundation of single vs. multisession screening, brief intervention and referral to treatment (SBIRT) for adolescents and parents in pediatric primary care; a NIAAA adolescent SBIRT trial in pediatric primary care; an NIAAA trial of an innovative alcohol telemedicine consultation intervention, studies of the implementation and outcomes of large-sclae alcohol screening and brief intervention, and an NIAAA survey of pediatrician attitudes toward and practices of adolescent behavioral-health risk screening and intervention. Dr. Sterling was co-investigator of a cluster-randomized trial of SBIRT for unhealthy alcohol use in adult medicine in Kaiser Permanente Northern California. She co-authored a widely disseminated issue brief, "Reducing Risky Alcohol Use: What Health Care Systems Can Do" and has developed nationally disseminated educational materials including NIAAA's "The Healthcare Professional's Core Resource on Alcohol, 'Promote Practice Change: Take Manageable Steps Toward Better Care'." Dr. Sterling is the KPNC Training Director for an innovative hybrid National Institute of Mental Health T32 fellowship program and was recognized with DOR's Excellence in Mentoring Award.

    She received her doctoral training at the University of North Carolina Gillings School of Global Public Health, and her master's degrees in Public Health and Social Welfare at the University of California, Berkeley.

    No Relevant Financial Disclosures

    Lorenzo Leggio

    MD. PhD, MSc

    Dr. Lorenzo Leggio serves as the Chief of the joint NIAAA/NIDA Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology. He received his M.D. and Ph.D. from the Catholic University of Rome, where he also completed residency and Board Certification in Internal Medicine. He received a Masters in Alcoholism from the University of Florence. He was a postdoctoral research associate in Psychiatry and Human Behavior at Brown University. In 2010, he became Assistant Professor at the Brown University Center for Alcohol and Addiction Studies (CAAS). Dr. Leggio's clinical research has been primarily focused on the treatment of alcoholism, with an emphasis on the role of feeding-related and GABAergic pathways; and on the medical consequences of alcoholism, with an emphasis on alcoholic liver disease. While at Brown, he received funding from NIH and various foundations. In 2012, Dr. Leggio joined NIAAA and NIDA as a joint Clinical Investigator and Section Chief. He is licensed and credentialed as Senior Attending Medical Staff at the NIH Clinical Center. Dr. Leggio also serves as the Associate Director for Clinical Research for the NIDA IRP Medication Development Program. Additionally, he is an Adjunct Associate Professor at the Brown University CAAS. Dr. Leggio's lab has pioneered clinical research on the role of neuroendocrine signaling in alcoholism. He has authored or co-authored over 100 peer-reviewed manuscripts and has served as reviewer for NIH study sections and other U.S. and international funding agencies. He has served as consultant for FDA advisory panels, and on the editorial boards of addiction-related journals. He has served as Chair (Clinical) of the 2016 Research Society on Alcoholism (RSA) Program Committee. Among other awards, he received the 2008 ESBRA Nordmann Award, the 2015 NIAAA Clinical Service Award, the 2016 NIAAA Mentoring Award, and the 2016 RSA Early Career Investigator Award

    No Relevant Financial Disclosures

    Rajita Sinha, PhD

    Foundations FUND Professor of Psychiatry, Neuroscience and Child Study

    Yale University

    Rajita Sinha, Ph.D. is the Foundations Fund Endowed Professor in Psychiatry, and Professor in Neuroscience and in Child Psychiatry at the Yale University School of Medicine. She is a licensed Clinical Psychologist and Clinical Neuroscientist, Chief of the Psychology Section in Psychiatry and Deputy Chair in Psychiatry for Psychology at the Yale University School of Medicine. She is the founding director of the Yale Interdisciplinary Stress Center that focuses on understanding the neural and psychobiological mechanisms underlying stress, trauma and alcohol and substance use behaviors as well as related conditions such as chronic pain, comfort food intake and obesity. She has developed novel drug craving, stress, pain and food reward provocation paradigms to understand mechanisms that drive these states and related pathologies. Her lab has also developed and tested novel pharmacological and behavioral interventions to address alcohol and substance use behavior change in the context of stress and trauma to decrease addiction relapse risk. She has received a number of awards for her work, including the recent Research Society on Alcoholism’s Distinguished Researcher Award in 2020, and also the James Tharp Award from the American Society of Addiction Medicine. Her research has been supported by a series of NIH funded research projects continuously for over 20 years. She has published over 325 scientific peer reviewed publications with an H-Index of 98 on Google Scholar and has been cited over 37,000 times. She currently serves on the National Scientific Advisory Council of NIDA and is on the National Institutes of Health’s (NIH) Expert Scientific Panel for the NIH Common Fund’s Science of Behavior Change program. She has also previously served as a member of the NIH/NIAAA Scientific Advisory Council. She has presented at numerous national and international conferences, and her work is widely cited.

    Does Disclose: CT Pharma,LLC. Received a research grant to study medical cannabis for chronic pain.

    Charles Marmar, MD

    Lucius N. Littauer Professor and ChairDirector, Center for Precision Medicine in Alcohol Use Disorder and PTSD

    Department of PsychiatryNYU Langone Health

    Dr. Marmar is Lucius N. Littauer Professor and Chair, Department of Psychiatry, New York University Grossman School of Medicine, and Director of the NYU Langone Center for Precision Medicine in Alcohol Use Disorder and PTSD. Previously, Dr. Marmar was Professor & Vice Chair of the Department of Psychiatry at UCSF, & Associate Chief of Staff for Mental Health & Director of the PTSD Research Program at the San Francisco VA Medical Center. Dr. Marmar graduated from the University of Manitoba with a BSc in 1966 and an MD in 1970. He completed his residency in Psychiatry and Fellowship in Neuropsychopharmacology at the University of Toronto in 1976 and a Psychiatry Fellowship at the University of California, San Francisco in 1978.
    Internationally renowned for his expertise in PTSD for over 35 years, his focus ranges from combat-related conditions in veterans, including Iraq and Afghanistan vets, to PTSD in refugees and earthquake victims. He has served on multiple committees and scientific advisory groups at the national level for both the VA and the National Institute of Mental Health (NIMH) and as counsel to the VA Medical Centers, fire departments, disaster response teams and police departments, including the NYPD. An award-winning teacher and researcher, Dr. Marmar is currently the principal investigator of numerous PTSD-related grants funded by NIAAA, the Department of Defense and private philanthropic organizations. He conducts studies in psychopharmacology, psychopathology, and psychobiology, quality of care, psychotherapy treatment and phenomenology of PTSD. He has served as president of the international societies for traumatic stress studies, and has published nearly 350 peer-reviewed manuscripts and chapters.

    Does Disclose: Advisory Board for Otsuka Pharmaceuticals- Received honorarium for serving in advisory board for PTSD; Consultant for Roche Received honorarium for serving in advisory board for PTSD.

    ACCME Accredited with Commendation

    CME, CE, CEU and Other Credit Types

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals
    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)
    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)
    This educational program is approved by CADTP: #205

    California Consortium of Addiction Programs and Professionals (CCAPP)
    This educational program is approved by CCAPP: #OS-20-330-1222

    Continuing Education Credits (CEUs)
    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC) / Continuing Certification Program (CCP)

    The ASAM State of the Art Course  meets the CME requirements for the following primary boards:
    • American Board of Medical Specialties (ABMS)
    • American Board of Preventive Medicine (ABPM)
    • American Board of Anesthesiology (ABA)
    • American Board of Pediatrics (ABP)
    • American Board of Internal Medicine (ABIM)
    • American Board of Surgery (ABS)
    • American Board of Psychiatry and Neurology (ABPN)
    • American Board of Addiction Medicine (ABAM)
    • Royal College of Physicians and Surgeons of Canada (RCPSC

    Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include mitigating all possible relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee member and Presenters have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.